It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
Image source: Getty Images
Breville Group Ltd (ASX: BRG)
According to a note out of Morgan Stanley, its analysts have retained their overweight rating and $36.50 price target on this home appliance manufacturer's shares. Morgan Stanley believes that Breville will report solid earnings growth when it releases its FY 2025 results later this month. And looking ahead, while there are concerns about the impact of US tariffs on its business, the broker downplayed this. It believes any impact from US tariffs will be manageable. This is thanks to the company's options to offset them with pricing, product mix, and cost efficiencies. In addition, Morgan Stanley highlights that Breville is exposed to favourable global coffee trends. Combined with its expansion into China, the broker thinks it is well-placed for growth over the medium term. The Breville share price ended the week at $33.96.
Rea Group Ltd (ASX: REA)
A note out of Bell Potter reveals that its analysts have upgraded this property listings company's shares to a buy rating with an improved price target of $284.00. Bell Potter was happy with the realestate.com.au operator's full year results release last week. And, importantly, it feels confident REA Group's strong form can continue. In fact, Bell Potter is expecting earnings per share growth of approximately 20% in both FY 2026 and FY 2027. Another positive is its strong free cash flow profile. The broker highlights that this means it is able to make sustained platform reinvestment to target double-digit yield growth through the cycle. This includes a next-gen listings platform to drive CX and higher quality leads for users. The REA share price was fetching $245.86 on Friday.
ResMed Inc. (ASX: RMD)
Analysts at Citi have retained their buy rating on this sleep disorder treatment company's shares with an increased price target of $49.00. According to the note, ResMed delivered a full year result ahead of expectations in FY 2025 thanks to stronger than expected revenue and gross margins. And with management guiding to higher margins in FY 2026, Citi is feeling confident about its outlook over the next 12 months. So much so, it suspects that it could outperform the market's expectations again. The ResMed share price was trading at $43.02 at Friday's close.
